Levodopa/Benserazid Devatis (Benserazide, Levodopa)

Levodopa is absorbed from the gastrointestinal tract and crosses the blood‑brain barrier, where it is converted into dopamine by aromatic L‑amino acid decarboxylase. The added benserazide blocks this conversion in peripheral tissues, allowing more levodopa to reach the brain and restore dopaminergic neurotransmission.

The specific dose and dosing schedule are determined by the prescribing clinician based on the individual’s disease severity, response, and tolerability. Physicians typically start with a low dose and titrate upward to achieve optimal symptom control while minimizing side effects.

Safety data for use in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Healthcare providers should weigh potential benefits against risks and consider alternative therapies when treating pregnant or nursing individuals.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Levodopa/benserazide is considered the most effective symptomatic therapy for Parkinson’s disease because it directly replenishes dopamine. Compared with dopamine agonists, it often provides stronger motor improvement but may have a higher risk of motor complications such as dyskinesia over long‑term use.

Store the product at ambient temperature, preferably below 25 °C. Keep it in the original packaging, protect it from moisture and direct light, and ensure the container is tightly closed to maintain stability throughout its shelf life.

The medication is taken orally, usually with a glass of water. It may be taken with or without food, but high‑protein meals can interfere with absorption, so clinicians often advise spacing the dose away from protein‑rich foods.

Serious risks include the development of dyskinesia (involuntary movements), psychiatric disturbances such as hallucinations or psychosis, and severe orthostatic hypotension. Patients should be monitored regularly for these events, and any sudden changes should be reported to a healthcare professional.

Individuals with known hypersensitivity to levodopa, benserazide, or any excipients should avoid the product. It is also contraindicated in patients taking non‑selective MAO inhibitors and those with narrow‑angle glaucoma or severe cardiovascular disease without careful medical supervision.